MiniMed Group, a diabetes technology company and subsidiary of Medtronic, has begun trading on the Nasdaq Global Select Market under the ticker “MMED,” following its initial public offering. The listing marks a step in Medtronic’s effort to establish MiniMed as a more independent entity while maintaining a majority ownership stake, allowing the business to operate with greater autonomy in the diabetes device market.
Medtronic said the offering was oversubscribed and ranks as one of the largest IPOs in medtech, highlighting continued investor interest in diabetes care technologies. MiniMed develops integrated systems for diabetes management, including insulin delivery devices, continuous glucose monitoring, and software designed to work together as a unified platform.
The separation is intended to give MiniMed more flexibility to scale its technology and respond to market demands, while allowing Medtronic to allocate capital toward other areas of its healthcare portfolio. The move reflects ongoing activity in diabetes care, where companies are focusing on connected device ecosystems that combine hardware, data, and algorithms to support more continuous and automated treatment.